Leerink Partners analyst David Risinger reiterated a Buy rating on Roivant Sciences today and set a price target of $32.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
David Risinger has given his Buy rating due to a combination of factors that highlight Roivant Sciences’ promising future. The company has demonstrated a potential for increased long-term profitability, as indicated by the recent analyst meeting where management outlined plans for reduced operating expenses and smaller projected losses in the coming years. This optimistic outlook is further supported by the expectation of significant profitability starting in fiscal year 2029.
Additionally, Roivant Sciences has a robust pipeline with several upcoming milestones, including multiple commercial launches and regulatory filings by the end of 2028. The acceleration of clinical timelines, particularly for brepocitinib across three indications, underscores the company’s progress in advancing its drug development programs. Furthermore, with a strong cash position of $4.4 billion, Roivant is well-capitalized to achieve its strategic goals and fund its priorities, reinforcing confidence in its financial stability and growth potential.
In another report released today, Goldman Sachs also maintained a Buy rating on the stock with a $33.00 price target.